PRKCD and scleroderma: Not surprisingly, a recent study revealed that pharmacological inhibition of PKCδ leads to profound changes in the transcriptome of fibroblasts from patients with scleroderma, a disease linked with inflammation, with NF-κB transcription factors playing a central role in the control of those genes [33].